About Beeline Therapeutics

About company

Beeline is an early-stage preclinical cell therapy company developing the next generation of immune cell therapies for immune-mediated human disease, particularly diseases which result from the patient's own immune cells attacking healthy tissue. We are genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo and induce tolerance. In particular, we are re-engineering Regulatory T cells (Tregs) to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins, and combining enhanced Treg function with antigen specificity via targeting receptors for improved localization.